Last updated: August 24, 2026
Vantas is a once-yearly histrelin acetate implant for androgen-deprivation therapy in men with advanced prostate cancer. Its commercial position has weakened materially because of manufacturing and supply interruptions, limited market scale, competition from injectable GnRH agonists and antagonists, and the absence of separately reported product revenue. Vantas is not a major current growth asset for Endo Pharmaceuticals. Its commercial value is primarily tied to supply restoration, physician familiarity, and the technical difficulty of developing an implant-based generic or alternative product.
What is Vantas and what market does it serve?
Vantas contains 50 mg of histrelin acetate in a subcutaneous implant designed to release histrelin continuously for 12 months. The product suppresses testosterone through pituitary GnRH receptor desensitization and is indicated for the palliative treatment of advanced prostate cancer in adults.[1]
| Product attribute |
Vantas |
| Active ingredient |
Histrelin acetate |
| Dosage form |
Subcutaneous implant |
| Strength |
50 mg |
| Administration |
One implant intended for 12 months |
| Primary indication |
Advanced prostate cancer |
| FDA application |
NDA 021264 |
| Original sponsor |
Indevus Pharmaceuticals |
| Commercial rights |
Subsequently associated with Endo Pharmaceuticals |
| Therapeutic class |
GnRH agonist, androgen-deprivation therapy |
| Main alternatives |
Leuprolide, goserelin, triptorelin, degarelix, relugolix |
| Delivery distinction |
Annual implant rather than injection or oral therapy |
Vantas occupies a narrow segment of the prostate-cancer hormonal-therapy market. Its value proposition is reduced administration frequency. Patients do not require monthly, three-monthly, four-monthly, or six-monthly injections, although implantation and removal require a minor surgical procedure.
The product is clinically distinct from Supprelin LA, another histrelin acetate implant marketed for central precocious puberty. Supprelin LA contains 50 mg of histrelin acetate but has a different FDA indication and commercial market. Vantas and Supprelin LA should not be treated as interchangeable products for revenue, prescribing, or regulatory analysis.
What is the FDA regulatory status of Vantas?
Vantas received FDA approval in 2004 under NDA 021264.[2] The approved product remains a prescription drug and is regulated as a drug-device combination involving a drug-releasing implant and an insertion system.
The principal regulatory risks have related to commercial availability rather than a publicly reported withdrawal for safety or efficacy. FDA drug-shortage and discontinued-product records have reflected availability problems for histrelin implant products, including manufacturing-related constraints affecting Vantas supply.[3]
A product may remain FDA-approved while being commercially unavailable. That distinction is important for Vantas:
| Regulatory question |
Vantas status |
| FDA approval |
Approved under NDA 021264 |
| Approval basis |
New drug application |
| Safety withdrawal |
No broad safety withdrawal established in the cited public record |
| Commercial availability |
Subject to supply and manufacturing constraints |
| Generic approval |
No widely marketed substitutable generic equivalent identified in the cited sources |
| Orange Book role |
Relevant for NDA and patent/exclusivity review, but does not guarantee commercial supply |
An FDA listing as approved does not mean that pharmacies or oncology practices can reliably obtain the implant. For Vantas, supply continuity is a more important commercial variable than the existence of an active approval alone.
When does Vantas lose exclusivity?
Vantas is an old approved product, and its original regulatory exclusivity has expired. FDA approval in 2004 means the five-year new chemical entity exclusivity period would have ended no later than 2009, subject to the specific regulatory classification and any applicable pediatric extension.[4]
The key commercial barrier is therefore not regulatory exclusivity. It is the complexity of reproducing and commercializing a sterile, implantable, controlled-release product.
| Exclusivity type |
Vantas position |
| New chemical entity exclusivity |
Expired |
| Three-year clinical-investigation exclusivity |
No longer commercially relevant |
| Orphan-drug exclusivity |
Not the principal protection for Vantas |
| Pediatric exclusivity |
No current commercial significance |
| Patent protection |
Any meaningful original protection would be aged; current scope requires patent-record verification |
| Practical market protection |
Manufacturing complexity, limited volume, physician workflow, and market-entry economics |
A competitor would generally face more than a conventional tablet-generic challenge. It would need to demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy the applicable FDA pathway for a long-acting implant. Device performance, release characteristics, sterility, insertion mechanics, packaging, and implant-site performance can all affect development risk.
What patents protect Vantas?
Vantas has historically been associated with intellectual property covering histrelin delivery, implant composition, controlled release, and related administration technology. The commercial significance of those rights has declined as the product has aged.
The most important distinction is between:
- Patents covering the active pharmaceutical ingredient or broad implant technology.
- Patents covering a particular implant formulation or manufacturing method.
- Patents covering the approved use in advanced prostate cancer.
- Patents listed for the specific NDA in the FDA Orange Book.
- Patents that have expired, been disclaimed, or become irrelevant to a current generic pathway.
Publicly available product labeling and FDA sources do not establish a current, broad patent barrier that would independently preserve Vantas market exclusivity. The FDA Orange Book is the controlling source for patents formally listed against an approved NDA, while USPTO records are required to assess continuation applications, terminal disclaimers, maintenance fees, and expiration calculations.[5][6]
How strong is the Vantas patent estate?
The Vantas patent estate appears commercially weaker than the product’s formulation and manufacturing barriers.
| Patent-estate factor |
Commercial assessment |
| Age of approval |
Limits remaining term for original platform patents |
| Active ingredient |
Histrelin is an established peptide drug, reducing composition-of-matter protection value |
| Implant technology |
Can create technical entry barriers but may not block all alternative designs |
| Manufacturing process |
Potentially important if process claims remain enforceable |
| Method of use |
Likely narrower than a broad product patent |
| Orange Book-listed protection |
Must be checked against the current FDA listing and patent status |
| Generic challenge exposure |
Moderate in theory, but development economics reduce practical entry |
The strongest remaining protection would likely come from product-specific formulation or manufacturing claims, not from the age of the active ingredient. A challenger could potentially design around individual claims by changing polymer composition, implant geometry, loading, release profile, or manufacturing sequence, subject to FDA comparability requirements.
What formulations are protected by Vantas?
Vantas uses a polymer-based implant that releases histrelin acetate over approximately one year. The formulation is materially different from injectable depot products and oral androgen-receptor pathway drugs.
The implant creates several technical barriers:
- Maintaining a consistent 12-month release profile.
- Controlling peptide stability during manufacture and storage.
- Producing a sterile implant with reproducible dimensions.
- Demonstrating consistent insertion and removal performance.
- Matching exposure over the full dosing interval.
- Establishing acceptable implant-site tolerability.
- Validating packaging and shelf life.
These factors increase development costs relative to a conventional small-molecule tablet. They also make a simple ANDA substitution less predictable from a commercial standpoint, even where the active ingredient and dosage strength are known.
Are there Vantas Paragraph IV challenges?
No major, widely documented Paragraph IV litigation campaign against Vantas is identified in the principal public FDA and company sources cited here.
That does not eliminate generic risk. It indicates that the market has not produced a prominent, publicly established patent challenge comparable with high-revenue oral drugs. Paragraph IV activity is less attractive when the reference product has limited sales, uncertain supply, a complex implant presentation, and substantial clinical or device-development requirements.
A generic applicant could pursue:
- An ANDA with patent certifications.
- A 505(b)(2) application using Vantas data or published literature to support a modified implant.
- A new NDA for a technically differentiated histrelin implant.
- A different androgen-deprivation product that competes clinically without copying Vantas.
The absence of a visible Paragraph IV case is therefore not evidence of durable patent exclusivity. It is more consistent with a low-value, technically difficult target.
Which companies are challenging Vantas?
The principal competitive pressure does not come from a named Vantas generic challenger. It comes from companies marketing other androgen-deprivation treatments.
| Competitor |
Company or principal commercial sponsor |
Product type |
Competitive effect |
| Lupron Depot |
AbbVie |
Leuprolide injection |
Established injectable standard |
| Eligard |
Tolmar |
Leuprolide injection |
Multiple dosing intervals |
| Zoladex |
AstraZeneca |
Goserelin implant |
Long-acting implant competitor |
| Trelstar |
Veru |
Triptorelin injection |
Injectable GnRH agonist |
| Firmagon |
Ferring |
Degarelix injection |
GnRH antagonist with rapid testosterone suppression |
| Orgovyx |
Myovant, now within Sumitomo Pharma structure |
Oral relugolix |
Oral alternative without an implant procedure |
| Supprelin LA |
Endo-related commercial franchise |
Histrelin implant |
Different indication: central precocious puberty |
Orgovyx is a particularly important strategic competitor because oral administration eliminates the need for implant insertion. Injectable products remain more established in urology and oncology practices and often have reimbursement and office-administration infrastructure that supports adoption.
How does Vantas compare with competing prostate-cancer drugs?
Vantas is differentiated by annual administration but disadvantaged by the implantation procedure and supply reliability.
| Dimension |
Vantas |
Injectable GnRH agonists |
Oral GnRH antagonist |
| Administration |
Annual implant |
Monthly to annual injections |
Daily oral dosing |
| Procedure required |
Yes |
Injection |
No procedure |
| Testosterone suppression |
Continuous after initial pharmacologic effect |
Continuous after initial effect |
Rapid suppression with relugolix |
| Clinic economics |
Implant and procedure revenue potential |
Office injection economics |
Pharmacy and adherence economics |
| Supply sensitivity |
High because of specialized implant manufacturing |
Usually lower product complexity |
Tablet manufacturing |
| Switching flexibility |
Lower once implanted |
Moderate |
High, subject to adherence |
| Generic substitution potential |
Technically difficult |
More established pathways |
Increasingly exposed over time |
Vantas can be attractive for patients who prefer fewer treatment visits and for clinicians seeking durable testosterone suppression. The implant can be less attractive when immediate treatment adjustment, rapid reversibility, or avoidance of a procedure is important.
What is the financial trajectory of Vantas?
Endo has not consistently reported Vantas as a standalone revenue line in its public financial statements. The company has generally reported product sales within broader branded-pharmaceutical categories or aggregated product groups.[7][8] As a result, a precise annual Vantas revenue series cannot be derived from Endo’s consolidated filings.
The financial trajectory is best characterized as follows:
| Period |
Financial interpretation |
| Early commercialization |
Specialty product with differentiated annual implant dosing |
| Mature period |
Niche revenue base constrained by a single indication and competing depot therapies |
| Supply-disruption period |
Revenue volatility and possible prescription displacement |
| Current strategic position |
Limited disclosed contribution; low visibility as a growth asset |
| Forward outlook |
Dependent on reliable manufacturing, product availability, and retention of specialist prescribers |
The principal revenue risks are operational:
- Lost prescriptions during periods when Vantas cannot be supplied.
- Permanent conversion of patients to leuprolide, degarelix, relugolix, or other therapies.
- Reduced purchasing by clinics that cannot plan around uncertain inventory.
- Higher manufacturing costs per unit because of limited production volume.
- Lower negotiating leverage with payers and distributors.
- Generic or 505(b)(2) entry if the market becomes large enough to support development.
The product’s financial upside is also limited by market size. Advanced prostate cancer is a substantial treatment market, but Vantas competes for only the subset of patients and physicians who value annual implantation. The commercial opportunity is much smaller than the total androgen-deprivation therapy market.
What licensing deals affect Vantas?
Vantas originated with Indevus Pharmaceuticals and became associated with Endo through the transfer and consolidation of product rights. Public company filings are the principal source for determining the exact scope of manufacturing, commercialization, and licensing rights at each point in time.[7]
No major recent licensing transaction has publicly repositioned Vantas as a high-growth asset. The product is better understood as part of a mature specialty-pharmaceutical portfolio than as a platform asset with significant partnering momentum.
Licensing value would depend on:
- Rights to the Vantas NDA.
- Access to the validated manufacturing process.
- Control of the implant supplier.
- Responsibility for postmarketing obligations.
- Rights to any surviving formulation or process patents.
- Ability to restore supply without substantial capital expenditure.
What generic launch risks exist for Vantas?
A generic or follow-on launch would face both regulatory and commercial risk.
Regulatory and technical barriers
The applicant would need to establish equivalence for a long-acting implant rather than only demonstrate dissolution and systemic exposure. FDA expectations could include data addressing release kinetics, drug content uniformity, sterility, implantation, explantation, and local tolerability.[4]
Commercial barriers
Even a successful approval may not produce a viable return. The Vantas market has limited volume, and a new entrant would need to support:
- Specialized manufacturing.
- Sterile production.
- Urology and oncology sales coverage.
- Implant training.
- Distribution to specialty clinics.
- Reimbursement support.
- Inventory planning for a product with long dosing intervals.
A generic launch could therefore occur without producing aggressive price erosion if only one technically capable entrant appears. Conversely, a reliable competitor could rapidly take share during any Vantas supply interruption.
What patent litigation affects Vantas?
No major current Vantas patent litigation is established in the cited public sources. The litigation risk is more likely to arise from future follow-on entry than from active enforcement of a high-value patent estate.
Potential disputes could involve:
- Orange Book-listed formulation patents.
- Process patents covering polymer manufacture.
- Patent-term calculations.
- Paragraph IV certifications.
- Inequitable-conduct or invalidity defenses.
- Patent-infringement claims against a 505(b)(2) implant.
- Device-related intellectual property outside the Orange Book.
The absence of visible litigation lowers near-term litigation expense but does not materially improve the product’s growth outlook.
What is the outlook for Vantas revenue?
Vantas revenue is likely to remain niche and operationally sensitive. The most plausible commercial scenarios are:
| Scenario |
Market outcome |
| Supply restored and stable |
Revenue stabilizes at a modest specialty-product level |
| Continued intermittent availability |
Further physician switching and declining installed base |
| Successful follow-on entrant |
Price and volume pressure, with potential expanded access |
| Endo deprioritization |
Reduced promotion, limited inventory, and eventual commercial contraction |
| Product relaunch or manufacturing transfer |
Temporary improvement, but limited long-term growth without new indications |
Vantas has no obvious path to blockbuster-scale revenue under its current indication. Its value lies in cash generation from a mature niche franchise, provided manufacturing and distribution remain reliable.
Key Takeaways
- Vantas is a 12-month histrelin acetate implant for advanced prostate cancer.
- FDA approval was granted in 2004 under NDA 021264.
- Original regulatory exclusivity has expired.
- The product’s practical protection comes more from implant manufacturing complexity and market economics than from obvious remaining exclusivity.
- No major publicly documented Paragraph IV challenge or current Vantas patent litigation campaign is identified.
- Endo does not consistently disclose standalone Vantas revenue, preventing a precise product-level financial model from public filings.
- Supply reliability is the central commercial variable.
- Leuprolide, goserelin, triptorelin, degarelix and oral relugolix create substantial competitive pressure.
- Supprelin LA should be analyzed separately because it has a different FDA indication.
- A follow-on implant could face high technical and commercial barriers despite the age of the reference product.
FAQs
Is Vantas still FDA-approved?
Yes. Vantas was approved under FDA NDA 021264. Approval status and commercial availability are separate issues, and the product has experienced supply and manufacturing constraints.[1][2]
Is Vantas interchangeable with Supprelin LA?
No. Both contain histrelin acetate in an implant, but Vantas is approved for advanced prostate cancer and Supprelin LA is approved for central precocious puberty.
Does Vantas have a generic equivalent?
No widely marketed generic equivalent is identified in the cited public sources. The implant format creates greater development complexity than a conventional oral generic.
Can Vantas compete with Orgovyx?
Yes, but the products have different administration models. Vantas offers annual implantation, while Orgovyx is an oral GnRH antagonist that avoids an implant procedure and provides rapid testosterone suppression.
What is the biggest investment risk for Vantas?
The principal risk is commercial erosion from unreliable supply and substitution by injectable or oral androgen-deprivation therapies. Patent expiry is less important than manufacturing continuity and the limited scale of the addressable niche.
References
- DailyMed. (n.d.). Vantas: Histrelin acetate implant, prescribing information. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (2004). FDA approves Vantas histrelin acetate implant for advanced prostate cancer.
- U.S. Food and Drug Administration. (n.d.). Drug shortages and discontinued drug product records.
- U.S. Food and Drug Administration. (2019). Draft guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant or animal origin.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Patent and Trademark Office. (n.d.). Patent Center and patent term adjustment and expiration records.
- Endo International plc. (2021). Annual report on Form 10-K for the fiscal year ended December 31, 2020.
- Endo International plc. (2022). Annual report on Form 10-K for the fiscal year ended December 31, 2021.
